Rezolute, Inc.

NasdaqCM:RZLT Stock Report

Market Cap: US$348.9m

Rezolute Management

Management criteria checks 3/4

Rezolute's CEO is Nevan Elam, appointed in Jan 2013, has a tenure of 13.33 years. total yearly compensation is $2.85M, comprised of 21.4% salary and 78.6% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth $308.97K. The average tenure of the management team and the board of directors is 5.1 years and 5.7 years respectively.

Key information

Nevan Elam

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage21.42%
CEO tenure13.3yrs
CEO ownership0.09%
Management average tenure5.1yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Analysis Article • Feb 16

Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Oct 14

Here's Why We're Not Too Worried About Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 18

Rezolute: Late-Stage Study Targeting Hyperinsulinism

Summary Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses. Despite a small market size and competition from diazoxide, RZLT's innovative approach and phase 3 data potential make it a compelling, albeit cautious, investment. Read the full article on Seeking Alpha
Analysis Article • Feb 03

Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. Indeed, Rezolute ( NASDAQ:RZLT ) stock...
Analysis Article • May 22

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 13

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Key Insights Rezolute's estimated fair value is US$0.87 based on 2 Stage Free Cash Flow to Equity Rezolute's US$1.14...
Analysis Article • Sep 21

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Rezolute fair value estimate is US$2.26 Rezolute is estimated...
Analysis Article • Jul 25

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 31

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 15

Rezolute GAAP EPS of -$0.37

Rezolute press release (NASDAQ:RZLT): Q4 GAAP EPS of -$0.37. Cash and cash equivalents totaled $150.4 million as of June 30, 2022.
Analysis Article • May 06

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 12

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

If you want to know who really controls Rezolute, Inc. ( NASDAQ:RZLT ), then you'll have to look at the makeup of its...

CEO Compensation Analysis

How has Nevan Elam's remuneration changed compared to Rezolute's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$81m

Dec 31 2025n/an/a

-US$84m

Sep 30 2025n/an/a

-US$77m

Jun 30 2025US$3mUS$611k

-US$74m

Mar 31 2025n/an/a

-US$73m

Dec 31 2024n/an/a

-US$71m

Sep 30 2024n/an/a

-US$69m

Jun 30 2024US$1mUS$550k

-US$68m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023n/an/a

-US$57m

Sep 30 2023n/an/a

-US$56m

Jun 30 2023US$974kUS$534k

-US$52m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022n/an/a

-US$44m

Sep 30 2022n/an/a

-US$43m

Jun 30 2022US$8mUS$515k

-US$41m

Mar 31 2022n/an/a

-US$38m

Dec 31 2021n/an/a

-US$31m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021US$5mUS$496k

-US$21m

Mar 31 2021n/an/a

-US$18m

Dec 31 2020n/an/a

-US$19m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020US$4mUS$490k

-US$20m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019n/an/a

-US$37m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019US$732kUS$453k

-US$33m

Compensation vs Market: Nevan's total compensation ($USD2.85M) is about average for companies of similar size in the US market ($USD2.65M).

Compensation vs Earnings: Nevan's compensation has increased whilst the company is unprofitable.

CEO

Nevan Elam (58 yo)

13.3yrs
Tenure
US$2,851,109
Compensation

Mr. Nevan Charles Elam, J.D., is a Founder of Rezolute, Inc. and serves as its Chief Executive Officer and Director at since January 31, 2013. Mr. Elam serves as Acting Chairman of the Board at Rezolute, I...

Leadership Team

NamePositionTenureCompensationOwnership
Nevan Elam
Founder13.3yrsUS$2.85m0.089%
$ 309.0k
Daron Evans
Chief Financial & Business Officer2.3yrsUS$1.72m0.27%
$ 959.0k
Brian Roberts
Chief Medical Officer6.3yrsUS$1.43m0.11%
$ 374.4k
Michael Deperro
Senior VP & Head of Operationsno datano datano data
Davelyn Hood
Director and Head of Scientific & Patient Affairs5yrsno datano data
Melissa Quinn
Senior Director of People and Cultureno datano datano data
Michael Covarrubias
Senior VP & Head of Program & Portfolio Management5.2yrsno datano data
Chris Milks
VP & Head of Financeno datano datano data
Raj Agrawal
VP & Head of Ophthalmological Clinical Developmentno datano datano data
Robyn Sweinhart
VP & Head of Qualityno datano datano data
Erin O'Boyle
Senior VP & Head of Clinical Operationsno datano datano data
Susan Stewart
Chief Regulatory Officer3.6yrsno datano data
5.1yrs
Average Tenure
54.5yo
Average Age

Experienced Management: RZLT's management team is seasoned and experienced (5.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nevan Elam
Founder13.3yrsUS$2.85m0.089%
$ 309.0k
Jerrold Olefsky
Member of the Scientific Advisory Board12.1yrsno datano data
Gilbert Labrucherie
Independent Director6.5yrsUS$296.16k0.051%
$ 178.9k
Philippe Fauchet
Independent Director5.7yrsUS$289.66k0%
$ 0
Young-Jin Kim
Director7.3yrsUS$267.16k0.11%
$ 385.6k
Scott Morenstein
Board Observerno datano datano data
Quan Dong Nguyen
Member of the Scientific Advisory Board5yrsno datano data
Nerissa Kreher
Independent Director5.2yrsUS$285.16k0.0029%
$ 10.3k
Robert B. Bhisitkul
Member of the Scientific Advisory Boardno datano datano data
Wladimir Hogenhuis
Independent Director5.2yrsUS$293.66k0.061%
$ 214.3k
Adrian Vella
Member of the Scientific Advisory Board4.7yrsno datano data
So-Hyun Kwon
Board Observerno datano datano data
5.7yrs
Average Tenure
55.5yo
Average Age

Experienced Board: RZLT's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 14:29
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rezolute, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Edward NashCanaccord Genuity
Pete StavropoulosCantor Fitzgerald & Co.